BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1% – Time to Sell?

BioAge Labs, Inc. (NASDAQ:BIOA) fell 6.1% on Wednesday . The company traded as low as $18.54 and last traded at $18.4050. 253,699 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 681,727 shares. The stock had previously closed at $19.61.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BIOA. Citigroup boosted their price objective on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Morgan Stanley set a $23.00 price objective on BioAge Labs in a research note on Wednesday, February 4th. Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Needham & Company LLC began coverage on BioAge Labs in a research note on Friday, March 27th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, Oppenheimer began coverage on BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective for the company. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.25.

BioAge Labs Stock Down 5.6%

The firm has a market cap of $821.61 million, a price-to-earnings ratio of -8.20 and a beta of 1.80. The stock has a fifty day moving average price of $19.09 and a 200-day moving average price of $14.54.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Tuesday, March 24th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. The business had revenue of $3.08 million for the quarter. BioAge Labs had a negative return on equity of 27.86% and a negative net margin of 896.11%. As a group, research analysts expect that BioAge Labs, Inc. will post -2.7 earnings per share for the current year.

Insider Activity

In other news, insider Paul D. Rubin sold 7,433 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of BIOA. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs in the third quarter valued at approximately $27,000. CWM LLC grew its holdings in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after acquiring an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares during the period. Walleye Capital LLC acquired a new position in BioAge Labs during the second quarter worth $64,000. Finally, Bank of America Corp DE grew its holdings in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after acquiring an additional 3,517 shares during the period.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.